AlphaStocks
7.2
Consider Buy

NOVARTIS AG (NVS)

Health Care

ADR

$159.90

Above average across most dimensions. A solid candidate.

Consider Buy

Score based on 4 of 5 models — moderate confidence

#46out of 1121 in Health Care

Is NOVARTIS AG a Good Investment in 2026?

NOVARTIS AG (NVS) scores 7.2 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates NOVARTIS AG as Strong (9/9). The Graham model is the least favorable, rating it Neutral. NOVARTIS AG currently trades below its estimated fair value of $223, suggesting potential upside. NOVARTIS AG ranks #46 out of 1121 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E22.4ROE31.5Market Cap313BDiv Yield2.5

Estimated Fair Value

$223.1728% below

Fair value above market price. EPS grew 22% year-over-year. ROE of 32% signals strong profitability. P/E of 22x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

9/9

Buffett

Strong

Business quality & competitive moat

Graham

Neutral

Significantly above fair value

Lynch

Strong

Growth rate vs price (PEG)

Greenblatt

Attractive

Top 10% (rank 6%)

Frequently Asked Questions

Is NOVARTIS AG (NVS) a good investment?
Based on AlphaStocks' composite analysis, NOVARTIS AG (NVS) scores 7.2 out of 10, earning a Consider Buy rating. This places it above average across most investment dimensions. Fair value above market price. EPS grew 22% year-over-year. ROE of 32% signals strong profitability. P/E of 22x is moderate for this quality level.
What is NOVARTIS AG's Piotroski F-Score?
NOVARTIS AG's Piotroski F-Score status is Strong. The raw score is 9/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is NVS overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $223, NVS appears undervalued. The stock currently trades 28% below its estimated fair value. Fair value above market price. EPS grew 22% year-over-year. ROE of 32% signals strong profitability. P/E of 22x is moderate for this quality level.
How does NVS compare to other Health Care stocks?
NOVARTIS AG ranks #46 out of 1121 stocks in the Health Care sector, placing it in the top 4% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about NVS?
AlphaStocks evaluates NVS using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Neutral; Lynch: Strong; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 7.2/10.

Similar Stocks

PARRBFAMAZN

Compare NVS with

NVS vs PARRNVS vs BFAMNVS vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer